ATTBF

Abattis Bioceuticals Corp.

 
Ordinary Shares International Reporting
OTCQB
Verified Company Profile 9/07/2016
Contact Info
  • Suite 104
  • 9295 198th Street
  • Langely, BC V1M3J9
  • Canada

Business Description


 
Financial Reporting/Disclosure
Reporting Status International Reporting: Canadian Securities Exchange
Audited Financials Audited
Latest Report Jun 30, 2016 Quarterly Report
CIK 0001515768
Fiscal Year End 9/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Business Status Development Stage Company a/o
Incorporated In: British Columbia, Canada
Year of Inc. 1997
Employees Not Available
Company Officers/Contacts
Rene David CFO, COO
Michael Bluestein Legal Counsel
Company Directors
Guy Dancosse
James Irving
Brazos Mishew
Douglas Sorocco
Company Notes
  • Formerly=Abattis Biologix Corp. until 9-2012
Service Providers
Accounting/Auditing Firm
Deloitte & Touche LLP
1055 Dunsmuir Street
Suite 2800
Vancouver, V7X 1P4
Canada

Legal Counsel Investor Relations Firm
ATTBF Security Details
Share Structure
Market Value1 $11,842,262 a/o Dec 06, 2016
Authorized Shares Unlimited a/o Sep 06, 2016
Outstanding Shares 107,656,928 a/o Sep 06, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 91,134,125 a/o Sep 06, 2016
Par Value Not Available
Shareholders
Shareholders of Record 199 a/o Sep 06, 2016
Non US Stock Exchange Listing
ATT - Canadian Securities Exchange - Qualified
Short Selling Data
Short Interest 75,437 (404.12%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security